What KOA BIOTECH BAY does

KOA BIOTECH BAY CO., LTD. (コーアバイオテックベイ株式会社) is a Japan-based pharmaceutical manufacturer founded in July 2002 and headquartered in Kohoku-ku, Yokohama. The company develops, manufactures, and sells generic (post-patent) prescription pharmaceuticals across multiple therapeutic categories — including cardiovascular (Amlodipine), anti-herpes virus (Famciclovir), osteoporosis (Minodronic acid, Zoledronic acid), ophthalmology (Latanoprost), antibiotics (Levofloxacin), and amino-acid/metabolic agents (Levocarnitine) — alongside contract manufacturing and packaging services for other pharmaceutical companies. Following the July 1, 2022 absorption merger with group company KOA Pharmaceutical Co., Ltd., the portfolio was extended to include OTC pharmaceuticals (NSAIDs, steroid ointments) and health food products, some based on traditional Japanese herbal formulas (Kampo).

The company holds First-class and Second-class manufacturing/marketing authorizations plus a general pharmaceutical manufacturing license, and operates under international GMP-compliant quality systems. Products reach end-users through Japan's pharmaceutical wholesale distribution network to hospitals, clinics, and pharmacies for the prescription portfolio, and through retail channels for the OTC and health food portfolio. Marketing to healthcare professionals is conducted via medical-representative (MR) field activities and dedicated information channels.

KOA Biotech Bay is a privately held subsidiary of KOA SHOJI HOLDINGS CO., LTD., part of a diversified Japanese trading group. Capital is stated at 10 million yen, the management team is lean (President Kazunari Fukunaga plus two Directors and one Auditor), and the operating geography is exclusively Japan. Revenue, headcount, and external funding are not publicly disclosed. The company describes its strategic mission as contributing to stable supply of generic medicines and reducing patient healthcare burden in Japan's super-aging society.

Name

KOA BIOTECH BAY

Legal name

KOA BIOTECH BAY CO., LTD.

Website

https://biotechbay.jp

Company type

Private

Founded year

2002

Operating status

Operating

Short description

KOA BIOTECH BAY is a Japan-based, privately held pharmaceutical manufacturer that develops, produces, and sells generic prescription drugs plus OTC and health food products, serving hospitals, pharmacies, and consumers exclusively through Japanese distribution channels.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Generic pharmaceuticals
• OTC medicines
• Contract manufacturing
• Pharmaceutical packaging
• Health supplements

Headquarters

HQ city

Yokohama

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Generic pharmaceutical manufacturing and sales: Development, manufacturing, and sales of generic (post-market) pharmaceutical products, including tablet, injection, and ophthalmic formulations.
2. Contract manufacturing and packaging: Pharmaceutical manufacturing (packaging) commissioned by other pharmaceutical companies.
3. OTC pharmaceuticals and health food sales: Over-the-counter (non-prescription) pharmaceuticals and health food products sold directly to consumers, added following the July 2022 merger with KOA Pharma Co., Ltd.

Distribution channels1 record

Marketing channels1 record

Core offering

KOA BIOTECH BAY develops, manufactures, and sells generic (post-patent) prescription pharmaceuticals in tablet, injection, and ophthalmic formulations covering therapeutic areas such as cardiovascular, anti-herpes virus, osteoporosis, ophthalmology, and anti-infectives. The company also provides contract pharmaceutical manufacturing and packaging services to other pharmaceutical firms and, following the July 2022 merger with KOA Pharmaceutical, distributes OTC medicines and health foods directly to consumers.

Product overview

KOA BIOTECH BAY CO., LTD. is a Japanese pharmaceutical company specializing in generic drugs, OTC medicines, and health products. The company operates as a contract manufacturer and seller of ethical pharmaceutical products, offering a portfolio of generic medications (including anti-herpes virus agents, calcium channel blockers, bisphosphonates, antibiotics, and eye drops) alongside OTC pharmaceuticals (NSAIDs, steroid ointments, and traditional Japanese herbal medicines) and nutritional health supplements. The company absorbed KOA Pharmaceutical Co., Ltd. in July 2022, expanding from generic drugs to include OTC medicines and health foods.

Differentiator

Problem solved

Functional benefit

Products and services

• Famciclovir Tablets 250mg "YD" (ファムシクロビル錠250mg「YD」) Anti-herpes virus agent generic drug for treating herpes simplex and varicella-zoster virus infections, supplied to medical institutions and pharmacies.
• Amlodipine Tablets "TYK" (アムロジピン錠「TYK」) Generic calcium channel blocker tablets for treatment of hypertension and angina, supplied to medical institutions and pharmacies.
• Minodronic Acid Tablets "Mikasa" (ミノドロン酸錠「三笠」) Generic bisphosphonate tablets for treatment of osteoporosis, supplied to medical institutions and pharmacies.
• Levofolinate IV Infusion "BT" (レボホリナート点滴静注用「BT」) Generic folinic acid IV formulation used as an antidote for methotrexate and in combination chemotherapy, supplied to medical institutions.
• Latanoprost Eye Drops "AA" (ラタノプロスト点眼液「AA」) Generic prostaglandin analog eye drops for glaucoma and ocular hypertension treatment, supplied to medical institutions and pharmacies.
• Zoledronic Acid IV Infusion Bag "Yakult" (ゾレドロン酸点滴静注バッグ「ヤクルト」) Generic bisphosphonate IV infusion for hypercalcemia of malignancy and bone metastases treatment, supplied to medical institutions.
• Levocarnitine Chloride Tablets "YD" (レボカルニチン塩化物錠「YD」) Generic carnitine supplement tablets for carnitine deficiency treatment, supplied to medical institutions and pharmacies.
• Levofloxacin Tablets "BT" (レボフロキサシン錠「BT」) Generic quinolone antibiotic tablets for various bacterial infections, supplied to medical institutions and pharmacies.
• Nippon Clean FC (ニッポークリーンFC) Class 3 quasi-drug OTC supplement combining Vitamin B2, B6, and C for skin conditions, acne, and inflammation relief.
• Loxoprofen Tablets "GX" (ロキソプロフェン錠「GX」)
• Dermapearl Ointment (デルマパール軟膏)
• Traditional Japanese Herbal Medicine Portfolio (陀羅尼助丸, 五苓散, 当帰芍薬散, 桂枝茯苓丸, 芍薬甘草湯, 半夏厚朴湯, 桔梗湯)
• Poliguro A (ポリグロンa)
• Buraseru M2Z Plus (ブラセルM2Zプラス)
• Pharmaceutical Contract Manufacturing and Packaging Service Pharmaceutical manufacturing (packaging) services commissioned by other pharmaceutical companies, leveraging the company's specialized packaging capabilities.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• KOA Pharma Co., Ltd. (コーア製薬株式会社)coreStrategic or Co-development Partner · 1 July 2022KOA Pharma Co., Ltd. was absorbed through a merger on July 1, 2022. This merger expanded KOA Biotech Bay's portfolio from solely generic pharmaceuticals to include OTC drugs and health foods, significantly broadening the company's product offerings and market reach.
• Mitsubishi UFJ Bank Musashi-Kosugi Branch (三菱UFJ銀行　武蔵小杉支店)minorOthersPrimary banking partner for the company.
• KOA Shōji Holdings Co., Ltd. (コーア商事ホールディングス株式会社)coreOthersParent/holding company. Related group companies include KOA Shōji Co., Ltd. and KOA Isei Co., Ltd.
• KOA Shōji Co., Ltd. (コーア商事株式会社)minorOthersRelated group company.
• KOA Isei Co., Ltd. (コーアイセイ株式会社)minorOthersRelated group company.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Market position

Weaknesses1 record

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KOA BIOTECH BAY